SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy

NCT06676722 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Cancinoma (NPC)
SBRT
Immunotherapy

Interventions

DRUG: SBRT combined with Nimotuzumab followed by Tislelizumab

Sponsor

The First Affiliated Hospital of Xiamen University